Peer-Reviewed Original Research Articles |
| 1. | Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/2009. PMID: 19470929. |
| 2. | Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16):2598-603, 6/2009. e-Pub 1/2009. PMID: 19164203. |
| 3. | Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res 3(3):90-6, 5/2009. PMCID: PMC2713134. |
| 4. | Blazer DG, Kishi Y, Maru D, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Nauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 26(33):5344-51, 11/20/2008. e-Pub 10/20/2008. PMID: 18936472. |
| 5. | Overman M, Kopetz S. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park) 22(13):1482-3, 11/30/2008. PMID: 19227576. |
| 6. | Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abburzzese J, Ajani J, Wolff Ra. Chemotherapy with 5-fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma. Cancer 113(8):2038-2045, 10/15/2008. PMID: 18759326. |
| 7. | Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-54, 10/2008. e-Pub 6/5/2008. PMID: 18528634. |
| 8. | Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 10/2008. PMID: 18798063. |
| 9. | Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla E, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: A report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067. |
| 10. | Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol 26(12):2000-5, 4/20/2008. PMID: 18421052. |
| 11. | Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lmyphoma. Ann Oncol 19(3):553-9, 3/2008. e-Pub 12/13/2007. PMID: 18083690. |
| 12. | Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer 7(1):55-9, 1/2008. PMID: 18279578. |
| 13. | Overman MJ, Hoff P. EGFR-targeted Therapies in Colorectal Cancer. Dis Colon Rectum 50(8):1-13, 8/2007. PMID: 17566832. |
| 14. | Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 92(4):886-7, 10/2004. PMID: 15499705. |
| 15. | David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 17(6):1077-86, 12/2000. PMID: 11078791. |
| 16. | Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270(41):23895-8, 10/1995. PMID: 7592576. |
Invited Articles |
| 1. | Cusack JC, Overman MJ, Wolff RA. Diagnosis and staging of small bowel neoplasms. UpToDate.com, 1/2009. |
| 2. | Cusack JC, Overman MJ, Wolff RA. Epidemiology, clinical features, and types of small bowel neoplasms. UpToDate.com, 1/2009. |
| 3. | Cusack JC, Overman MJ, Wolff RA. Treatment of small bowel neoplasms. UpToDate.com, 1/2009. |
Abstracts |
| 1. | Overman MJ, Hu C, Wolff RA, Chang GJ. Impact of lymph node evaluation on survival for small bowel adenocarcinoma: Analysis of the surveillance, epidemiology, and end results. ASCO 2009 Annual Meeting (#4596), 5/2009. |
| 2. | Shroff R, Javle M, Varadhachary G, Krishnan S, Crane C, Wen S, Abbruzzese J, Wolff R, Overman M,J. Improved relapse-free survival with the addition of systemic chemotherapy to adjuvant chemoradiation for high risk ampullary adenocarcinoma. GI ASCO 2009 (#250), 1/2009. |
| 3. | Kopetz S, Hoff PM, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. GI ASCO 2009 (#292), 1/2009. |
| 4. | Kazmi SM, Phan, Jhamb J, Mani M, Tetzlaff E, Lin E, Ajani J, Abbruzzese JL, Overman MJ. Toxicity and efficacy of a weekly based docetaxel, cisplatin, and 5FU(DCF) as first-line treatment of advanced gastric and esophageal cancer. GI ASCO 2009 (#68), 1/2009. |
| 5. | Overman MJ, Varadachary G, Lin E, Morris J, Adinin R, Abbruzzese JL, Wolff RA. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. ASCO 2008 (#4538), 5/2008. |
| 6. | Overman MJ, Kopetz S, Wen S, Morris J, Ajani J, Hoff P, Abbruzzese JL, Wolff RA. "A retrospective Analysis of Platinum-based chemotherapy in the treatment of metastatic adenocarcinoma of the small bowel". GI ASCO 2007 (#172), 1/2007. |
| 7. | Kopetz S, Pathak P, Chadha R, Overman MJ, Eng C, Glover K, Change DZ, Wolff RA, Hoff PM, Abbruzzese JL. "Second-line chemotherapy utilization in metastatic colorectal cancer may vary by disease responsiveness". GI ASCO 2007 (#313), 1/2007. |
| 8. | Overman MJ, Chedid S, Morris J, Waldrum S, Wolf RA. "A phase II Study of Capecitabine and Oxaliplatin (CAPOX) in metastatic adenocarcinoma of the small bowel or ampulla of Vater". GI ASCO 2007 (#139), 2007. |
| 9. | Overman MJ, Barbara P, McLaughlin P, Samaniego F, Younes A, Romaguera J, Hagemeister F, Kwak L, Rodriguez MA, Fayad L. "Favorable results of Rituximab in combination with CHOP in the front-line treatment of follicular lymphoma grade 3". ASH 2006 (#2770), 12/2006. |
| 10. | Kopetz S, Dang J, Overman MF, Phan L, Feig B, Patell D, Wolff RA, Eng C, Abbruzzese JL, Hoff PM. "Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: a single-institution retrospective study". ASCO 2006 (#3579), 5/2006. |
| 11. | Overman MJ, Wang C, Detrano R, Douglas-Escobar M, lpp E, Hara B, Layos E, Shames E, Swerdloff R, Berman N, Chlebowski R. "Cardiovascular Risk in Prostate Cancer: Patients with and without Androgen Ablation". ASCO 2004 (#4605), 5/2004. |
